Curacef Duo, 50 mg/ml / 150 mg/ml, Suspension for Injection for Cattle

Summary of Product characteristics

                                Revised: October 2019
AN: 00636/2019
Page 1 of 8
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
CURACEF DUO, 50 mg/ml / 150 mg/ml, Suspension for injection for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains
ACTIVE SUBSTANCES:
Ceftiofur (as hydrochloride)
50.0 mg
Ketoprofen
150.0 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Off - white to pinkish suspension
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of bovine respiratory disease (BRD) caused by
_Mannheimia _
_haemolytica_ and _Pasteurella multocida _susceptible to ceftiofur and
the reduction
of associated clinical signs of inflammation or pyrexia.
4.3
CONTRAINDICATIONS
Do not use in cases of known resistance to other cephalosporins or
beta-
lactam antibiotics.
Do
not
use
in
cases
of
hypersensitivity
to
ceftiofur
and
other

-lactam
antibiotics.
Do not use in cases of hypersensitivity to ketoprofen.
Do not use in poultry (including eggs) due to risk of spread of
antimicrobial
resistance to humans.
Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs)
and
corticosteroids concurrently or within 24 hours of each other.
Revised: October 2019
AN: 00636/2019
Page 2 of 8
Do not use in animals suffering from cardiac, hepatic or renal
disease, where
there is the possibility of gastro-intestinal ulceration or bleeding,
where there is
evidence of a blood dyscrasia.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Avoid use in any dehydrated, hypovolaemic or hypotensive animals as
there is
a potential risk of increased renal toxicity.
4.5
SPECIAL PRECAUTIONS FOR USE
i) Special precautions for use in animals
In
case
of
the
occurrence
of
allergic
reaction
the
treatment
should
be
withdrawn.
The product selects for resistant strains such as bacteria carrying
extended
spectrum betalactamases (ESBL) and may constitute a risk to human
health if
these strains disseminate to humans e.
                                
                                Read the complete document